Sources of Variability in Manufacturing of Cell Therapeutics
暂无分享,去创建一个
[1] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[2] Elisa A. Hurley,et al. The Next Phase of Human Gene-Therapy Oversight. , 2019, The New England journal of medicine.
[3] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[4] Sheng Lin-Gibson,et al. Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century , 2017 .
[5] Alexander M Bailey,et al. An FDA perspective on preclinical development of cell-based regenerative medicine products , 2014, Nature Biotechnology.
[6] Simon Ellison,et al. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. , 2019, Cytotherapy.
[7] Scott R. Burger,et al. Making the grade: untangling the myths of raw materials used for the manufacture of cell- & gene-based medicinal products , 2018 .
[8] Anne Marsden,et al. International Organization for Standardization , 2014 .